GenTrust’s Boston Scientific BSX Stock Holding History

GenTrust’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,475	Closed	-$218K	–	211
2026 Q1	$218K	Buy	+3,475	New	+$278K	0.01%	256

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

GenTrust's BSX Position: Q2 2026 in Review

GenTrust sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 3,475 shares — an estimated $218K sold.

GenTrust first reported a position in BSX in Q1 2026 and held it in 1 quarter. The position peaked at $218K in Q1 2026. 1,477 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

GenTrust reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
GenTrust sold 3,475 Boston Scientific shares in Q2 2026, an estimated $218K.
GenTrust first reported a position in Boston Scientific in Q1 2026 and held it in 1 quarter.
GenTrust's Boston Scientific position peaked at $218K in Q1 2026.
1,477 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on GenTrust's 13F filing for Q2 2026, filed 6 Aug 2026.